<DOC>
	<DOCNO>NCT02817828</DOCNO>
	<brief_summary>The objective study evaluate contraceptive efficacy , vaginal bleeding pattern ( cycle control ) , general safety acceptability 15 mg estetrol ( E4 ) /3 mg drospirenone ( DRSP ) combination healthy woman age 18 50 year .</brief_summary>
	<brief_title>E4 FREEDOM ( Female Response Concerning Efficacy Safety Estetrol/Drospirenone Oral Contraceptive Multicentric Study ) - EU/Russia Study</brief_title>
	<detailed_description />
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Heterosexually active female risk pregnancy request contraception . Negative serum pregnancy test subject enrollment . Willing use investigational product primary method contraception 13 consecutive cycle . Good physical mental health basis medical , surgical gynecological history , physical examination , gynecological examination , clinical laboratory , vital sign . Body mass index ( BMI ) equal ( ≤ ) 35.0 kg/m2 . Able fulfill requirement protocol indicated willingness participate study provide write informed consent ( IC ) . Willing able complete diary questionnaire . Known hypersensitivity investigational product ingredient . Smoking ≥ 35 year old , screen . Any condition associate decrease fertility . Dyslipoproteinemia require active treatment antilipidemic agent . Diabetes mellitus vascular involvement ( nephropathy , retinopathy , neuropathy , ) diabetes mellitus 20year duration . Arterial hypertension . Any condition associate increase risk venous thromboembolism and/or arterial thromboembolism . Any condition associate abnormal uterine/vaginal bleeding . Abnormal Pap test base current international recommendation . Presence undiagnosed breast mass . Current symptomatic gallbladder disease . History COC related cholestasis . Presence history severe hepatic disease . Presence history pancreatitis associate hypertriglyceridemia . Porphyria . Presence history hepatocellular adenoma malignant liver tumor . Renal impairment . Hyperkaliemia presence condition predispose hyperkaliemia . Presence history hormonerelated malignancy . History nonhormonerelated malignancy within 5 year screen . Subjects nonmelanoma skin cancer allow study . Use drug potentially trigger interaction COCs . History alcohol drug abuse ( include laxative ) within 12 month prior screen . Any condition could result altered absorption , excessive accumulation , impaired metabolism , altered excretion investigational product . Uncontrolled thyroid disorder . Participation another investigational drug clinical study within 1 month ( 30 day ) receive investigational drug within last 3 month ( 90 day ) prior study entry . Subjects participate oral contraceptive clinical study , use FDA/EU approve active ingredient , may enrol 2 month ( 60 day ) complete precede study . Sponsor , CRO Investigator 's site personnel directly affiliate study . Is judged Investigator unsuitable reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Estetrol</keyword>
</DOC>